WUNDER-MOBILITY
29.10.2021 08:32:05 CEST | Business Wire | Press release
Wunder Mobility , the international provider of software and hardware for new mobility services, has launched its first co-developed e-bike. Unveiled at the Wunder Mobility Summit 2021, the new bike has been designed in partnership with Yadea , specifically for shared use. It boasts an industry-topping range of 120km, comes with a speed of 25 km/h, and is specifically designed for European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028006347/en/
The e-bike’s launch follows the recent IPCC Intergovernmental Panel on Climate Change Sixth Assessment Report which drastically shows that CO2 emissions must be substantially reduced.
As an environmentally friendly mode of transport, bike-sharing is expected to grow 11% worldwide by 2025 . During COVID-19, spurred on by booming consumer demand, many city authorities have increased their efforts to make their cities more bike-friendly. Initiatives include pop-up lanes and new cycleways. Political commitments to a transition to the Green Economy continue to drive investment in cycling infrastructure.
Working with Yadea, the world’s largest manufacturer of electric two-wheel vehicles, Wunder Mobility's own e-bike is a leap forward in design to help shared mobility operators capitalise on increasing opportunity. The companies are building on their long-standing relationship with Wunder Mobility’s software integrating with Yadea vehicles since 2019.
Taking shared e-bike performance to the next level
This is the first time an e-bike has been co-designed with Wunder Mobility’s technology and insight at its core. It combines Wunder Mobility’s data-driven understanding of the needs of operators and their users with Yadea’s market leadership in design and manufacturing.
With a range of 120km the e-bike far exceeds the industry average of 70-80km and is based on rider biometrics which best fit the European market. It is equipped with a motor lock and a smart lock for dual security – a rear wheel cover enclosing the locking mechanism to prevent tampering and offering space for marketing purposes. A swappable battery, firmware updates over the air and a built-in IoT connector which comes with Wunder Mobility software provide further ease of use for operators.
Gunnar Froh, Founder and Chief Executive Officer of Wunder Mobility
, said:
“Cycling is one of the key solutions for reducing mobility emissions. Through our collaboration we have produced a better performing e-bike for both the operator and the cyclist. This will play a vital role in helping cities and their citizens to achieve green goals and boost wellbeing through exercise. Superior range, weight and security coupled to our powerful platform will enable more short city journeys and cleaner and healthier longer distance urban travel.”
Heidi Zang, Overseas Director at Yadea
,
said:
“The extensive market research, analysis and design development behind this e-bike has deepened our close collaboration with the team at Wunder Mobility. A market-dominating high range, low weight and uncomplicated maintenance sets new standards and complements the product portfolio of environmentally friendly urban mobility solutions. The simple and smooth design is unique in the sharing field, attracting consumers' attention and encouraging them to choose this e-bike.”
ENDS
Yadea:
Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea's mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.
For more information: www.yadea.com
.
Wunder Mobility:
Wunder Mobility is the global leader in software and hardware for new mobility services. The mobility tech company provides white-label solutions that enable enterprises, startups and cities worldwide to deliver sustainable, convenient and secure mobility.
100+ customers in over 900 cities on six continents use the Wunder Mobility platform to launch and scale new mobility services, manage and finance shared vehicle fleets, optimize daily operations, and improve urban planning and traffic management.
The global Wunder Mobility team, with more than 40 nationalities, consists of technology and mobility industry veterans. 50% of the team is in Product and Engineering. Wunder Mobility was founded in 2014 by Gunnar Froh and Sam Baker. The headquarters are in Hamburg, with additional locations in Dortmund and Los Angeles. For more information:
www.wundermobility.com
| LinkedIn
| Twitter
| YouTube
| Wunder Mobility Podcast
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006347/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom